Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An International, Multicentre, Open-label Study To Evaluate The Efficacy and Safety of Two Different Vaccination Regimens of Immunotherapy With Allogeneic Dendritic Cells, DCP-001, in Patients With Acute Myeloid Leukaemia That Are In Remission With Persistent MRD

Trial Profile

An International, Multicentre, Open-label Study To Evaluate The Efficacy and Safety of Two Different Vaccination Regimens of Immunotherapy With Allogeneic Dendritic Cells, DCP-001, in Patients With Acute Myeloid Leukaemia That Are In Remission With Persistent MRD

Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Dec 2018

At a glance

  • Drugs DCP 001 (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms ADVANCE II
  • Sponsors DCPrime
  • Most Recent Events

    • 16 Nov 2018 According to apceth Biopharma GmbH media release, the first patient has been treated in this trial with DCP-001 at the Amsterdam University Medical Center (UMC).
    • 31 Aug 2018 Biomarkers information updated
    • 24 Dec 2017 Status changed from planning to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top